They create rapid tests for new diseases. For example they were one of the first companies to make a COVID rapid test. They are currently working to develop a rapid molecular detection test for monkey pox, and have plans to unveil it by the end of the year. They made $5.9 million in revenue, which is lower than their sales expectations of $6.13 million, but that doesn’t explain why Yahoo is saying it’s overvalued at 12 cents. Can someone explain why?
Leave a Reply